🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Long-term Efficacy of Once Daily Versus Twice Daily Aspirin in High-risk MPN Patients With Aspirin Resistance

RecruitingPhase 3Ages 18 Years - anyAllSiriraj Hospital
NCT06740916 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Patients with myeloproliferative neoplasm (MPN) could have laboratory aspirin resistance and then increasing dose of aspirin from once daily to twice daily regimen is suggested. However, it is not routinely recommended to perform platelet function testing to determine aspirin resistance in MPN patients. Moreover, it is not known whether increasing dose of aspirin would always correct aspirin resistance and significantly prevent the thrombotic events in MPN patients. Therefore, this study aims to compare the efficacy of once daily versus twice daily aspirin in high-risk MPN patients with aspirin resistance. MPN patients with laboratory aspirin resistance will be included in this prospective randomized study and platelet function testing will be repeated at one and six months later. Clinical thrombosis and side effect from aspirin will be recorded for at least 2 years after intervention.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Philadelphia negative Myeloproliferative neoplasms aged at least 18 years old Exclusion Criteria: * Concomitant other active malignancy or cured less than 6 months * Platelet count less than 50,000/microL * Receiving anticoagulant * Active peptic ulcer * Active bleeding or Planning to undergo procedure/operation with bleeding risk * No laboratory aspirin resistance with LTA method
💊

What it tests

  • 81-mg aspirin once daily
  • 81-mg aspirin twice daily
📍

Where

1 site
Division of Hematology, Department of Medicine, Faculty of Medicine Siriraj Hospital
Bangkok Noi, Thailand
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy